Integer Holdings beats Q4 estimates, announces $50M buyback
Medical device manufacturer delivered 21% EPS growth for full year 2025 despite conservative 2026 outlook
Integer Holdings Corporation delivered better-than-expected fourth-quarter earnings and announced a $50 million accelerated share repurchase program, providing a modest boost to investor sentiment despite maintaining a cautious outlook for the coming year.
The medical device outsourced manufacturer reported adjusted earnings per share of $1.76 for the fourth quarter of 2025, exceeding analyst estimates of $1.68, according to earnings data from Seeking Alpha. Revenue increased 1.2% to $472.1 million for the quarter, topping projections that had anticipated sales of approximately $462.7 million.
For the full year 2025, Integer achieved 8% sales growth to $1.85 billion, with adjusted EPS expanding 21% to $6.40. The performance reflects the company's position as a key supplier to medical device manufacturers, though results came amid what management described as challenging demand conditions in certain product segments.
"Integer delivered solid operational execution in 2025 despite market headwinds, achieving both our sales growth and adjusted EPS targets for the year," the company stated in its earnings announcement.
The $50 million accelerated share repurchase program marks a significant capital allocation decision, representing roughly 1.7% of the company's current market capitalization of approximately $3 billion. With shares trading around $86.48 — well below their 52-week high of $144.76 — the buyback suggests management believes the stock is undervalued despite the near-term demand challenges.
Looking ahead, Integer reaffirmed its 2026 guidance, projecting sales of $1.83 billion to $1.88 billion and adjusted EPS of $6.29 to $6.78. The outlook reflects a conservative sales trajectory, with the company anticipating reported sales to either decline or grow by up to 2%, while organic sales are expected to remain unchanged or increase by up to 4%.
The muted growth forecast stems from reduced demand for several key products, including headwinds in electrophysiology and neuromodulation markets. Despite these challenges, Integer expects to maintain strong gross margins of approximately 27% over the next two years, according to analyst forecasts.
Analysts have adopted a cautious stance on the stock. The consensus price target stands at $85.57, according to market data, with ratings split between buy and hold recommendations. Some analysts have trimmed their price targets due to the softer 2026 outlook and reduced visibility on demand recovery.
Integer Holdings, headquartered in Plano, Texas, manufactures medical devices and components for customers across cardiac rhythm management, neuromodulation, orthopedics, and other medical specialties. The company operates facilities in the United States, Puerto Rico, Costa Rica, and internationally.
The stock's forward price-to-earnings ratio of 9.52 suggests investors are pricing in limited growth prospects, creating a potential opportunity if demand recovers faster than anticipated. However, with shares down significantly from their 2025 highs amid the broader healthcare sector rotation, much of the company's challenges may already be reflected in current valuations.
Investors will be watching for signs of stabilization in the electrophysiology and neuromodulation markets, as well as commentary on new product launches and customer win rates during subsequent earnings calls. The $50 million buyback program, while relatively modest, provides a floor under the stock and signals management's confidence in the underlying business despite near-term headwinds.